Skip to main content

Advertisement

Table 2 Significant changes in SDAI scores and circulating biomarker concentrations following 6 months DMARD therapy

From: Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis

Variable n Baseline 6 months P value
Median IQR Median IQR
SDAI 140 41.39 24.10 16 .00 15.81 0.0001
CRP (μg/ml) 140 17.10 42.25 8.90 17.35 0.0001
ACPA (IU/ml) 100 516.60 1027.75 255.65 677.20 0.0001
IL-4 (pg/ml) 32 4.70 10.28 1.51 6.53 0.0075
IL-7 (pg/ml) 123 20.32 82.22 16.69 23.46 0.0013
IL-8 (pg/ml) 123 8.79 12.65 5.70 7.09 0.0001
G-CSF (pg/ml) 123 13.82 60.02 7.23 51.61 0.0083
VEGF (pg/ml) 123 168.56 441.33 92.62 167.21 0.0010
Ratio IL-1 / IL-1Ra 37 0.05 0.05 0.03 0.06 0.0130
Ratio IL-17 / IL-10 30 10.42 15.61 3.72 3.81 0.0001
  1. Only those biomarkers which decreased significantly post-therapy are shown